LLY Stock Recent News
LLY LATEST HEADLINES
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Affirm Holdings Inc AFRM is a buy. “It's at $72, it's going to $100,” he noted.
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
I see Las Vegas' struggles as a mirror of broader economic woes of high prices, low consumer confidence, and trade uncertainty, pressuring markets and creating slim margins for error. I believe market overreactions to earnings misses present opportunities. High valuations demand strong growth, but fear-driven sell-offs can uncover undervalued, high-quality stocks. I highlight two iconic American companies with strong fundamentals, offering compelling risk/reward for long-term investors seeking reliable dividend growth in a volatile market.
Shares of Eli Lilly (LLY 1.49%), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its stock bounce back a modest 2.5% through 1:55 p.m. ET Monday on some positive news out of Wall Street.
LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral obesity pill.
Explore Lilly's (LLY) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly's price fell with a thud yesterday following underwhelming drug trial results as the markets completely ignored strong Q2 2025 results. LLY's drop is immediately reminiscent of a similar plunge for its rival Novo Nordisk a few days ago, and also only makes for a stronger Buy case. The company's position in the weight management market remains undisputed for now; it's also reported robust financials in Q2 2025 along with upgraded guidance.
Shares of Eli Lilly (LLY -2.37%) sank 18% this week, according to data from S&P Global Market Intelligence. The drugmaker with a market cap of over $500 billion is in a sharp drawdown due to previously high expectations and weak data on its obesity drug pipeline.
The Investment Committee debate the latest Calls of the Day and how to trade them.